CompletedNot applicableNCT01093885

Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Pennsylvania
Principal Investigator
Chris Derk, MD, MSc
University of Pennsylvania
Intervention
Ambrisentan(drug)
Enrollment
15 enrolled
Eligibility
19-90 years · All sexes
Timeline
2010 – 2016

Study locations (1)

Collaborators

Gilead Sciences

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01093885 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis →

← Back to all trials